Bilateral breast metastatic rectal cancer with MET gene amplification: A rare case report Authors: Dung Thi Nguyen, Thanh Huy Nguyen, Ha Thu Le, Hien Thu Truong Published: 2026 ABSTRACT AbstractBreast metastases originating from colorectal cancer are extremely rare, accounting for <0.5% of all malignant lesions of the breast and are often associated with histopathological forms with a poor prognosis, such as mucinous or signet-ring cells, in which bilateral breast metastases are even rarer. In this case report, we present a female patient in her early 50s. In April 2023, the patient was diagnosed with cT3N2M0 rectal cancer. After that, the patient underwent Miles surgery, followed by 12 cycles of mFOLFOX6 adjuvant chemotherapy, and received adjuvant chemoradiation therapy (50.4 Gy plus Capecitabine). The patient was discharged in January 2024. However, 7 months later, due to a palpable mass in her breast, the patient was found to have bilateral breast lesions and peritoneal metastases. Biopsies were taken from the lesions in both breasts and immunohistochemistry revealed that the tumors originated from the rectum with genetic testing detecting MET gene amplification. Thereafter, the patient was treated with many regimens, but the disease did not respond and progressed rapidly. The patient died six months after the recurrence of the disease was detected. In conclusion, breast metastases are a poor prognostic feature for colorectal cancer. Patients presenting with malignant breast lesions and a history of non-breast malignancy require careful differential diagnosis.Keywords: colorectal cancer, bilateral breast metastases, MET gene amplification, poor prognosis, case report Introduction Colorectal cancer (CRC) is the third most common type of cancer globally, and liver is the most common metastasis site, followed by the lungs, peritoneum, and bones.1,2 While breast cancer is the most common cancer in women, breast metastases from other cancers are rare, accounting for only 0.3-2% of all types of malignant breast tumors.1,3 Breast metastases from CRC are extremely rare, with a poor prognosis. 4 The survival time from the time of detection of breast metastases to the death of most patients is not more than 12 months. 5 Distinguishing between primary breast cancer and metastatic CRC to the breast is of critical clinical importance, as treatment strategies differ fundamentally between these two entities. Misdiagnosis can lead to therapeutic failure and significantly impact patient outcomes. Although several cases of CRC metastatic to the breast have been reported in the literature, most have focused primarily on clinical and histopathological descriptions, while molecular profile of these cases remains insufficiently analyzed. To our knowledge, this is among the first reported cases of bilateral breast metastases from rectal adenocarcinoma associated with MET amplification. The reporting of this case conforms to the CARE guidelines. 6 Case description The patient is a Vietnamese female in her early 50s. She had no history of smoking or alcohol consumption, and her family’s medical history had no information related to CRC or breast cancer. In April 2023, she presented with bloody mucous stools occurring several times a day. On digital rectal examination, a hard mass was palpable in the low rectum (approximately 4 cm from the anal verge). Through examination and test results, she was diagnosed with cT3N2M0 rectal cancer. She underwent Miles’ operation. Postoperative histopathological examination revealed a poorly differentiated adenocarcinoma with signet-ring cell features. The tumor invaded the perirectal tissue and blood vessels and metastasized to 12 out of 13 regional lymph nodes. Immunohistochemistry showed microsatellite stability (MSS). After surgery, the patient received adjuvant chemotherapy with mFOLFOX6 regimen for 12 cycles. She completed all 12 cycles without any major adverse events. After the end of chemotherapy, the patient continued to receive adjuvant chemoradiation therapy (concurrent radiation dose 50.4 Gy plus Capecitabine at a dose of 825 mg/m2 twice daily on days of radiation treatment) and was discharged in January 2024 (Table 1). Table 1.Timeline of diagnosis, interventions, and outcomes.DateClinical events & diagnosticsTherapeutic interventionsOutcomesApr 2023• Initial diagnosis: cT3N2M0 rectal cancer.• Pathology: Poorly differentiated adenocarcinoma with signet-ring cell.• Miles’ operation.• 12 cycles of mFOLFOX6 adjuvant chemotherapy.Stable.Jan 2024​• Adjuvant chemoradiation (50.4 Gy + Capecitabine).The patient is discharged.Aug 2024• Recurrence: Bilateral breast masses, peritoneal metastases, ascites.• CEA: 46.13 ng/mL.• Genetics: MET gene amplification.• First-line treatment: Bevacizumab + FOLFIRI.Disease progresses after 3 cycles.Nov 2024• Disease progression: Bone metastases (T10, L1, L2), breast tumors enlarged.• Second-line treatment: Bevacizumab + mFOLFOX6 + zoledronic acid.Second-line failure.Jan 2025• Disease progression: Pleural and perineal metastases, breast tumors invaded skin.• CEA: 313 ng/mL.• Third-line treatment: Regorafenib.Third-line failure. Poor tolerance to Regorafenib.Feb 2025• Rapid deterioration of performance status.• Palliative care only.Death (6 months after detection of recurrence). Timeline of diagnosis, interventions, and outcomes. In August 2024, the patient presented for a follow-up examination due to a palpable mass in her left breast. On physical examination, a 15 mm mass was noted in the left breast at the 10 o’clock position, and a 20 mm mass was detected in the right breast at the 12 o’clock position. These breast tumors were firm, ill-defined masses. Mammography demonstrated heterogeneous fibroglandular tissue bilaterally without calcifications, architectural distortion, or skin/nipple retraction. In the left breast, two masses were identified: an irregular, isodense mass with indistinct margins in the upper inner quadrant, and an oval, equal-density mass with indistinct margins at the 9 o’clock position (BIRADS II) (Figure 1). On ultrasound, the right breast showed a well-circumscribed hypoechoic nodule (11×8 mm) at the 11 o’clock position approximately 3 cm from the nipple (BIRADS III), and an ill-defined hypoechoic lesion (7×8 mm) at the 1 o’clock position approximately 4 cm from the nipple. No axillary lymphadenopathy was detected bilaterally. Contrast-enhanced chest CT demonstrated bilateral peripheral breast masses, measuring 16 mm on the right and 15 mm on the left, both located in the subcutaneous region with oval morphology, well-circumscribed margins, and contrast enhancement. Overall, the bilateral nature, peripheral location, absence of calcifications, and well-circumscribed appearance on CT are more consistent with metastatic deposits than primary breast malignancy. Abdominal CT scan showed abdominal peritoneal nodules (18 mm), and abdominal free fluid by about 20 mm (Figure 2). The results of blood biochemical tests showed that the CEA concentration increased to 46.13 ng/mL (reference range of 0.0-4.7 ng/mL) - this result at the time of discharge in January 2024 was 1.39 ng/mL. Mammography of the right (A), (B) and left (C), (D) breast glands. Chest and abdominal CT scan at the time of recurrence in August 2024. Lesions increase the density of the right (A) and left (B) breast glands. Peritoneal metastases (C) and abdominal fluid (D). We performed a needle biopsy of the bilateral breast tumors, the histopathology results showed that the mucinous adenocarcinoma had a signet-ring cell component. Immunohistochemical staining of the specimen revealed metastatic adenocarcinoma with signet-ring cell features, consistent with a colorectal origin: Mammaglobin negative, GCDFP-15 positive, GATA3 negative, CK20 positive, SATB2 positive, CDX2 positive, ER negative, PR negative (Figures 3 and 4). Histopathological images of breast biopsy on HE x40 (A) and x20 (B) stains with adenocarcinoma with typical signet-ring cells; consistent with histopathological images of primary tissue in the rectum, stained HE x200 is poorly differentiated mucinous adenocarcinoma (D), with signet-ring cell component (C). Breast lesion immunohistochemistry matched colorectal origin with (A) CK20 positive (x20), (B) CDX2 positive (x40), (C) SATB2 positive (x40), (D) GATA3 negative (x20), (E) ER negative (x20) and (F) PR negative (x40). Genetic analysis of the breast biopsy samples was performed using next-generation sequencing (NGS) on the NextSeq platform (Illumina, USA). Genomic DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue. Before DNA extraction, tumor purity was evaluated by a pathologist and confirmed to be greater than 80%. The NGS panel included the following genes: NRAS, KRAS, BRAF, PIK3CA, NTRK1/2/3, HER2, and MET, covering point mutations, short insertions/deletions, and copy number variations (CNV). Sequencing quality metrics included: average depth of 825.84, mapping rate of 100.00%, and 0.2X mean of 97.89%. The results showed no pathogenic mutations in NRAS, KRAS, BRAF, PIK3CA, NTRK1/2/3, or HER2. However, MET gene amplification was detected with a CNV of 3.64, which exceeded the predefined amplification threshold of ≥3.6. FISH confirmation was not performed in this case. The patient could not afford anti-EGFR therapy, so she received Bevacizumab-FOLFIRI regimen (Bevacizumab 5 mg/kg IV, Irinotecan 180 mg/m2 IV, Leucovorin 400 mg/m2 IV, 5-FU 400 mg/m2 IV bolus, followed by 5-FU 2400 mg/m2 IV continuous infusion over 46 hours, every 2 weeks). Although she had good tolerance, the disease progressed to metastasize to the T10, L1, and L2 bones, and the bilateral breast tumors continued to enlarge after 3 cycles in November 2024. Therefore, we decided to switch to the Bevacizumab plus mFOLFOX6 (Bevacizumab 5 mg/kg IV; Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV, 5-FU 400 mg/m2 IV bolus, followed by 5-FU 2400 mg/m2 IV continuous infusion over 46 hours, every 2 weeks) and zoledronic acid (4 mg intravenously every 4 weeks). After only 3 months, in January 2025, the disease continued to metastasize in the pleura, perineal tissue, and abdominal peritoneal nodules, which increased in both size and number. The bilateral breast tumors also continued to increase in size by about 5 cm and invaded skin. CEA concentrations continued to increase from 46.13 ng/mL as of August 2024 to 313 ng/mL as of January 2025. Because the disease progressed after second-line treatment, we decided to treat the patient with Regorafenib as third-line therapy. Following a dose-optimization strategy, the treatment was initiated at a low dose of 80 mg orally once daily. The patient expressed significant distress regarding the rapid progression of her disease and the physical burden of successive chemotherapy regimens, particularly during the third-line treatment with regorafenib. The patient’s condition deteriorated rapidly, and the regimen was poorly tolerated despite dose reduction, due to grade 3 fatigue, leading to treatment discontinuation after approximately one month. We decided to treat only with palliative care, and the patient died in February 2025. Discussion Breast metastases are very rare for cancer in general and colorectal cancer in particular. 7 As of 2020, only 46 cases of metastatic colorectal cancer of the breast have been reported; in these cases, the majority of breast metastases are on one side, and bilateral breast metastases account for only 10%.4,5 In cases where lesions are detected in the breast tissue, imaging tests such as mammography, computed tomography scans, or magnetic resonance imaging only help us to locate and assess local invasion. 8 To determine the origin of primary breast cancer or other cancers that have metastasized to the breast tissue, histopathological and immunohistochemistry analyses have decisive roles. Especially in female cases, missing the diagnosis can completely lead to treatment failure because the rate of cancer metastasis to the breast tissue is very rare. When colorectal cancer metastasizes to the breast, the tumors are typically highly aggressive, most commonly presenting as the mucinous and signet-ring cell type. 9 In the immunohistochemical profile, CK20, CDX2, and SATB2 were all strongly and diffusely positive, a combination highly specific for colorectal origin. 10 GATA3, ER, and PR were all negative, with appropriate internal positive controls confirmed for GATA3, further arguing against a breast primary. Mammaglobin was also negative, which is consistent with a non-breast origin. Notably, GCDFP-15 yielded a potentially confusing result: isolated nonspecific nuclear staining was observed, while cytoplasmic tumor positivity was absent. Cytoplasmic internal controls were appropriately positive, confirming adequate antibody performance and excluding a technical failure. GCDFP-15 positivity is more commonly associated with breast differentiation and would be unusual in colorectal metastasis; however, the staining observed in this case was focal nuclear rather than diffuse cytoplasmic, and therefore was interpreted as nonspecific. In the context of the overall immunoprofile — particularly the strong, diffuse expression of CK20, CDX2, and SATB2 — this isolated finding did not challenge the diagnosis of metastatic colorectal adenocarcinoma. The combined CK20+/CDX2+/SATB2+ immunophenotype strongly outweighed the equivocal GCDFP-15 result and reliably confirmed the colorectal origin of the breast lesions. CEA is a glycoprotein complex that is produced in almost all colorectal cancer cases and contributes to the malignant characteristics of the tumor. 11 A high level of CEA is considered a poor independent prognostic factor for colorectal cancer. 12 This is also relevant in our case: high level of CEA (46.13 ng/mL) at the time of detection of recurrence. Thereafter, as the disease continued to progress and did not respond to treatment regimens, CEA levels continued to rise to 313 ng/mL at the time of final assessment. MET (mesenchymal-epithelial transition) is an oncogene on chromosome 7q31 that encodes for the tyrosine kinase receptor and regulates multiple signaling pathways involved in stimulating tumor growth, survival, angiogenesis, invasion, and metastasis. 13 The rate of MET gene amplification mutations in colorectal cancer is quite low, from 1 to 4%, and it is also associated with a worse prognosis and resistance to anti-EGFR in treatment.14–16 For CRC patients with MET gene amplification mutations, several studies of targeted drug-antibody complexes such as telisotuzumab adizutecan or targeted drugs such as savolitinib have reported promising early results.17,18 This opens up new opportunities for patients, especially those who are resistant to chemotherapy. The patient has a simultaneous occurrence of MET amplification and MSS. Most MSS colorectal cancers develop along the chromosomal instability (CIN) pathway and are characterized by multiple copy number variants, including gain or loss of whole chromosome arms, typically 7q, 8q, and 20q. 19 In this context in genetics, local amplifications of proto-oncogenes located on these regions-such as MET at 7q31-are more likely to occur and be selected, thus providing a plausible biological mechanism to explain the occurrence of MET amplification in this patient’s MSS tumor. 15 The occurrence of MET amplification may have contributed significantly to the treatment resistance. Activated MET stimulates the PI3K–AKT and MAPK pathways, which confer resistance to kill cells of chemotherapy. HGF/MET also promotes VEGF biosynthesis in the hypoxic conditions after Bevacizumab treatment, leading to resistance to antiangiogenic therapy.15,20 This may explain the poor response to chemotherapy plus bevacizumab in this case. Our patient’s gene results did not detect mutations in KRAS, NRAS, BRAF, PIK3CA, NTRK1/2/3, or HER2. In principle, a RAS/BRAF wild-type, left-sided tumor without other targetable alterations would generally support the use of anti-EGFR–based combination chemotherapy as a first-line option. 21 However, the presence of MET amplification, together with the patient’s high metastatic burden and limited financial resources, may have reduced the likelihood and feasibility of anti-EGFR therapy, and bevacizumab-FOLFIRI was therefore selected as the first-line regimen. Then the disease progressed with first-line therapy, and the patient was switched to second-line treatment with FOLFOX regimen combined with Bevacizumab. After failing with the second-line regimen, for the third-line regimen, we used Regorafenib. However, the disease continued to progress, along with a high tumor burden, causing the patient’s condition to deteriorate rapidly, and she could only receive palliative care. 22 The patient survived 6 months following the diagnosis of breast metastasis, consistent with previously reported cases in which the survival time from the time of detection of breast metastases to the death of most patients is not more than 12 months. 5 Based on a literature search, we summarized 3 cases of colorectal cancer with bilateral breast metastases with full data that have been reported (Table 2). Table 2.Summary of published cases identified through literature review of bilateral breast metastases from colorectal cancer.NoAge/SexPrimary sitePathologyTime from primary CRC diagnosis to breast metastasis (months)Co-metastasesMolecular profileTreatmentSurvival after breast metastasis1 23 28/FRectumMucinous adenocarcinoma + signet-ring cell9None reportedIHC: ER−, PR−, HER2− NGS: Not performedNot reportedAlive at 2 months (follow-up ended)2 24 47/MRectumMucinous adenocarcinoma24None reportedIHC: Not reported, NGS: Not performedBilateral excision (regimen not reported)Not reported3 25 42/FColonMucinous adenocarcinoma24Adrenal gland, liver, abdominal lymphadenopathies, ascitesIHC: CK20+, CDX2+, CK7−, ER−, PR−, HER2−, P53 weakly positive PCR: KRAS mutationAdrenalectomy + FOLFOX -> FOLFIRI2 months Summary of published cases identified through literature review of bilateral breast metastases from colorectal cancer. While our report benefits from using an extensive IHC panel and next-generation sequencing to confirm this rare diagnosis, we recognize its limitations. Since this is a single observational case, we cannot definitively conclude that amplification caused the tumor to metastasize to the bilateral breasts. Although amplification is a proven mechanism for primary resistance to anti-EGFR drugs, its role in driving metastasis to unusual sites remains a hypothesis. We must avoid overgeneralizing these findings until larger molecular studies can investigate this potential link. Patient perspective The patient’s husband shared that, despite having been informed by the physicians about the poor prognosis at the time of recurrence, the disease progressed far more rapidly than the family had anticipated. The family expressed their gratitude to our hospital for our support throughout the course of treatment, which allowed the patient to pass away as peacefully as possible. Conclusion This case is proof of the aggressive malignancy, rapid progression, and atypical nature of mucinous adenocarcinoma colorectal cancer, which has a signet-ring cell component with metastasis to the bilateral breast, an extremely rare location in CRC. The role of biopsy of metastatic lesions and immunohistochemistry is critical in the diagnosis of primary cancer. In addition, genetic testing not only supports the selection of appropriate treatment regimens but also makes an important contribution to the prognosis of the disease. Acknowledgements We acknowledge the patient and all the participating authors for their contribution to the paper. Footnotes Author contributions: Study concept and design: N.T.D., T.T.H. Data acquisition: N.T.D., N.H.T. Data analysis and interpretation: N.T.D., N.H.T. Drafting of the manuscript: T.T.H., N.H.T. Critical revision of the manuscript for important intellectual content: N.T.D., L.T.H. Administrative, technical, or material support: T.T.H. Study supervision: L.T.H., T.T.H. Approval of final manuscript: N.T.D., L.T.H. Funding: The authors received no financial support for the research, authorship, and/or publication of this article. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. ORCID iDs Dung Thi Nguyen https://orcid.org/0000-0001-5798-8636 Thanh Huy Nguyen https://orcid.org/0009-0008-1652-0832 Ha Thu Le https://orcid.org/0009-0002-5868-5471 Hien Thu Truong https://orcid.org/0009-0006-5766-0220 Ethical considerations The requirement for ethics approval was waived because this study was a case report of a patient managed by our team, not an interventional study. Consent for publication Verbal and written informed consent for publication of this case report and accompanying images was obtained from the patient’s husband, as the patient had deceased prior to manuscript preparation. Data Availability Statement The data generated and analyzed during this study, including patient complaints, surgical details, histopathology, immunohistochemistry, and gene data, are not publicly available due to ethical and privacy restrictions to protect patient confidentiality. These data are recorded in departmental registers and are available from the corresponding author upon reasonable request.* References Associated Data Data Availability Statement The data generated and analyzed during this study, including patient complaints, surgical details, histopathology, immunohistochemistry, and gene data, are not publicly available due to ethical and privacy restrictions to protect patient confidentiality. These data are recorded in departmental registers and are available from the corresponding author upon reasonable request.*